Drug‐induced immune‐mediated thrombocytopenia secondary to durvalumab use

Immunotherapy is an expanding area of cancer treatment with significant promise. Despite their efficacy, checkpoint inhibitors are associated with a number of immune‐related adverse events; here, we described thrombocytopenia secondary todurvalumab.

Detalles Bibliográficos
Autores principales: Dougherty, Sean C., Lynch, Alia C., Hall, Richard D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218317/
https://www.ncbi.nlm.nih.gov/pubmed/34188921
http://dx.doi.org/10.1002/ccr3.4227
Descripción
Sumario:Immunotherapy is an expanding area of cancer treatment with significant promise. Despite their efficacy, checkpoint inhibitors are associated with a number of immune‐related adverse events; here, we described thrombocytopenia secondary todurvalumab.

Ejemplares similares